Blackstone’s next major bet is on a former Merck monoclonal antibody that a new biotech will test for asthma and COPD.
The alternative asset manager’s life sciences division, which recently inked a large financing deal with Moderna, will commit up to $300 million to support the new…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
